Combined General Meeting of May 25, 2023. Availability of the
preparatory documents
Daix (France), Long Island City (New York,
United States), May 4, 2023 – Inventiva (Euronext Paris
and Nasdaq: IVA), a clinical-stage biopharmaceutical company
focused on the development of oral small molecule therapies for the
treatment of patients with non-alcoholic steatohepatitis (NASH) and
other diseases with significant unmet medical needs, today
announced the availability of the preparatory documents for the
Combined General Meeting of May 25, 2023.
Shareholders are invited to participate in the
Combined General Meeting that will be held on May 25, 2023 at 2
p.m. at Hôtel Oceania Le Jura, 14 avenue Foch, 21000 Dijon
(France).
The preliminary notice of meeting comprising the
agenda and the draft resolutions, as well as information on how to
attend and vote at the Combined General Meeting, was published in
the Bulletin des Annonces Légales Obligatoires (BALO) n°46 of April
17, 2023 and a translation was filed with the Securities and
Exchange Commission on April 17, 2023.
Information and documents pertaining to the
Combined General Meeting are available in the Company's website
(www.inventivapharma.com, section "Investors" / "Shareholder
Meetings").
In accordance with articles R. 225-83 and
R. 225-89 of the French Commercial Code, documents that must be
available for the shareholders for the purpose of general meetings
will be available at the Company's registered office, 50, Rue de
Dijon, 21121 Daix, the fifteenth day prior to the Combined General
Meeting.
Documents listed in Article R.22-10-23 of the
French Commercial Code are available on Inventiva’s website
mentioned above as of tomorrow, the twenty-first day that precedes
the General Meeting.
In accordance with applicable regulatory
provisions:
- any shareholder holding registered shares may, up to the fifth
day, including, prior to the General Meeting, request these
documents to be sent by the Company. For shareholders holding
bearer shares, the exercise of this right is subject to the
submission of a shareholding certificate delivered by their
financial intermediary; and
- any shareholder may consult these documents at the Company's
registered office by sending a request by e-mail to the following
electronic address: AGIVA25012023@inventivapharma.com.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with NASH,
mucopolysaccharidoses (“MPS”) and other diseases with significant
unmet medical need. The Company benefits from a strong expertise
and experience in the domain of compounds targeting nuclear
receptors, transcription factors and epigenetic modulation.
Inventiva is currently advancing one clinical candidate, has a
pipeline of two preclinical programs and continues to explore other
development opportunities to add to its pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no
approved therapies.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting an oncology development candidate for its
Hippo signaling pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva Pascaline ClercVP of Global External
Affairsmedia@inventivapharma.com +1 240 620
9175 |
Brunswick GroupTristan Roquet Montegon /Aude
Lepreux /Matthieu BenoistMedia
relationsinventiva@brunswickgroup.com +33 1 53 96 83
83 |
Westwicke, an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements. These statements include,
but are not limited to, Inventiva’s pipeline and preclinical and
clinical development plans, future activities, expectations, plans,
growth and prospects. Certain of these statements, forecasts and
estimates can be recognized by the use of words such as, without
limitation, “believes”, “anticipates”, “expects”, “intends”,
“plans”, “seeks”, “estimates”, “may”, “will”, “would”, “could”,
“might”, “should”, and “continue” and similar expressions. Such
statements are not historical facts but rather are statements of
future expectations and other forward-looking statements that are
based on management's beliefs. These statements reflect such views
and assumptions prevailing as of the date of the statements and
involve known and unknown risks and uncertainties that could cause
future results, performance or future events to differ materially
from those expressed or implied in such statements. Actual events
are difficult to predict and may depend upon factors that are
beyond Inventiva's control. There can be no guarantees with respect
to pipeline product candidates that the clinical trial results will
be available on their anticipated timeline, that future clinical
trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals, or that any of the
anticipated milestones by Inventiva or its partners will be reached
on their expected timeline, or at all. Actual results may turn out
to be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, in the absence of which, Inventiva may be required
to significantly curtail, delay or discontinue one or more of its
research or development programs or be unable to expand its
operations or otherwise capitalize on its business opportunities
and may be unable to continue as a going concern, Inventiva's
future success is dependent on the successful clinical development,
regulatory approval and subsequent commercialization of current and
any future product candidates, preclinical studies or earlier
clinical trials are not necessarily predictive of future results
and the results of Inventiva's clinical trials may not support
Inventiva's product candidate claims, Inventiva’s expectations with
respect to the changes to the clinical development plan for
lanifibranor for the treatment of NASH may not be realized and may
not support the approval of a New Drug Application, Inventiva may
encounter substantial delays in its clinical trials or Inventiva
may fail to demonstrate safety and efficacy to the satisfaction of
applicable regulatory authorities, the ability of Inventiva to
recruit and retain patients in clinical studies, enrolment and
retention of patients in clinical trials is an expensive and
time-consuming process and could be made more difficult or rendered
impossible by multiple factors outside Inventiva's control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s business, and preclinical
studies and clinical development programs and timelines, its
financial condition and results of operations could be materially
and adversely affected by the current COVID-19 pandemic and
geopolitical events, such as the conflict between Russia and
Ukraine, related sanctions and related impacts and potential
impacts on the initiation, enrolment and completion of Inventiva’s
clinical trials on anticipated timelines, and macroeconomic
conditions, including global inflation, uncertain financial markets
and disruptions in banking systems. Given these risks and
uncertainties, no representations are made as to the accuracy or
fairness of such forward-looking statements, forecasts and
estimates. Furthermore, forward-looking statements, forecasts and
estimates only speak as of the date of this press release. Readers
are cautioned not to place undue reliance on any of these
forward-looking statements.
Please refer to the Universal Registration Document for the year
ended December 31, 2022 filed with the Autorité des Marchés
Financiers on March 30, 2023, and the Annual Report on Form 20-F
for the year ended December 31, 2022 filed with the Securities and
Exchange Commission on March 30, 2023 for additional information in
relation to such factors, risks and uncertainties.
All information in this press release is as of the date of the
release. Except as required by law, Inventiva has no intention and
is under no obligation to update or review the forward-looking
statements referred to above. Consequently, Inventiva accepts no
liability for any consequences arising from the use of any of the
above statements.
- Inventiva - PR - AGM - Availability of the preparatory
documents - EN - 04 05 2023
Inventiva (EU:IVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Inventiva (EU:IVA)
Historical Stock Chart
From Oct 2023 to Oct 2024